Clinical trials: Solid Tumors, completed
Neoplasms
STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS
A phase1 study to evaluate the PK (single dose and multiple doses) and safety of talazoparib 1 mg Once Daily in Chinese adult participants with advanced solid tumors.
- Trial name
- NCT04635631
- Testing
- talazoparib
- Where
- 2 sites in China
- Volunteers
- 15 people
- Sponsor
- Pfizer
Unspecified Adult Solid Tumor, Protocol Specific
Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer
RATIONALE: Paricalcitol may cause cancer cells to look more like normal cells, and to grow and spread more slowly. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either…
- Trial name
- NCT00217477
- Testing
- gemcitabine hydrochloride, paricalcitol
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Roswell Park Cancer Institute
Brain and Central Nervous System Tumors, Sarcoma
High-Dose Methotrexate in Treating Young Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as high-dose methotrexate work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00513981
- Testing
- leucovorin calcium, methotrexate, mass spectrometry
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 36 people
- Sponsor
- Children's Cancer and Leukaemia Group
Advanced Solid Tumours
Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours
This is a single-centre, open label, dose finding, phase I study to determine the recommended phase II dose (RP2D) for the combination of doxorubicin and pantoprazole in patients with advanced tumours and no standard treatment…
- Trial name
- NCT01163903
- Testing
- pantoprazole sodium for injection, doxorubicin hydrochloride injection
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- University Health Network, Toronto
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Virtual Mindfulness and Weight Management to Mitigate Risk of Relapse and Improve Wellbeing in Cancer Survivors
This clinical trial tests how well a virtual mindfulness and weight management program to mitigate risk of relapse and improve well being for obese cancer survivors in community practice and rural areas.
- Conditions
- Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm, Obesity-Related Malignant Neoplasm
- Trial name
- NCT06030427
- Testing
- Behavioral Dietary Intervention, Educational Intervention, Health Promotion and Education
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mayo Clinic
Advanced Solid Tumors
Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors
Single arm, open label, Phase I, dose-escalation study of indibulin in combination with erlotinib in subjects with advanced histologically confirmed, solid tumors for which no standard therapy exists and for whom treatment with…
- Trial name
- NCT00591383
- Testing
- indibulin, erlotinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Alaunos Therapeutics
Unspecified Adult Solid Tumor, Protocol Specific
Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors
RATIONALE: Dimethylxanthenone acetic acid may stop the growth of cancer cells by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of dimethylxanthenone acetic acid in treating patients with…
- Trial name
- NCT00003697
- Testing
- vadimezan
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- University of Glasgow
Solid Tumors
Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors
The purpose of this study is to determine the safety and maximal tolerated dose of NKP-1339, a ruthenium containing compound administered intravenously on a weekly schedule, in patients with advanced solid tumors.
- Trial name
- NCT01415297
- Testing
- NKP-1339
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Niiki Pharma Inc.
Unspecified Childhood Solid Tumor, Protocol Specific
Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving Anticonvulsants
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of irinotecan in treating children with refractory or…
- Trial name
- NCT00008424
- Testing
- irinotecan hydrochloride
- Where
- 51 sites in United States, Australia and 1 more
- Volunteers
- 7 people
- Sponsor
- Children's Oncology Group
Tumors
A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors
This is a Phase 1, open-label, randomized, 2-sequence, cross-over, pharmacokinetic (PK) study evaluating the effect of the DPD inhibitory action of CDHP as an S-1 component compared with FT alone on the PK of 5-FU in patients…
- Trial name
- NCT00400023
- Testing
- S-1, FT
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Taiho Oncology, Inc.
Cancer
A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors
The purpose of this study is to evaluate the safety and dose regimen of CNTO 888 when administered to patients with solid tumors in combination with 4 standard of care chemotherapy regimens.
- Trial name
- NCT01204996
- Testing
- CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection, CNTO888 + gemcitabine, CNTO888 + Paclitaxel and carboplatin
- Where
- 5 sites in United States, Spain
- Volunteers
- 53 people
- Sponsor
- Centocor, Inc.
Advanced Solid Tumors, Lymphoma
Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB
This is a phase 1, 2-part, open-label study in 4 to 6 pharmacokinetic-evaluable participants with advanced solid tumors or lymphoma.
- Trial name
- NCT01953783
- Testing
- IXAZOMIB
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Neoplasm
Study of TRC102 in Combination With Pemetrexed in Cancer Patients
This study is being performed to evaluate the safety and tolerability of TRC102 in combination with Alimta. In addition to safety, this study will also evaluate pharmacokinetics and tumor response.
- Trial name
- NCT00692159
- Testing
- TRC102 + pemetrexed
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Solid Tumor Cancer
Bioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in Humans
The test formulation of Trifluridine and Tipiracil Tablets (20 mg) is bioequivalent to the reference formulation (Lonsurf®) in Chinese patients with solid tumors under fed and fasting conditions.
- Trial name
- NCT07492173
- Testing
- Trifluridine and Tipiracil Tablets, Lonsurf®
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Advanced Solid Tumors, Multiple Myeloma
A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma
This study will determine the maximum tolerated dose (MTD) and/or the recommended phase II dose (RP2D) of single agent ONC201 in patients with advanced solid tumors or multiple myeloma.
- Trial name
- NCT02609230
- Testing
- ONC-201
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Fox Chase Cancer Center
Solid Tumours
To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
Study to assess the effect of Itraconazole and Fluconazole on the pharmacokinetics of Selumetinib (AZD6244; ARRY-142866) ( Hyd-Sulfate) in Healthy Male Volunteers
- Trial name
- NCT02093728
- Testing
- selumetinib, itraconazole, fluconazole
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Ototoxicity, Unspecified Adult Solid Tumor
Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin
RATIONALE: Alpha-lipoic acid may prevent or lessen hearing loss caused by cisplatin. PURPOSE: This randomized clinical trial is studying the effectiveness of alpha-lipoic acid in preventing hearing loss in cancer patients…
- Trial name
- NCT00477607
- Testing
- alpha-lipoic acid, Audiology, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- US Department of Veterans Affairs
Solid Tumor, Adult
Cannabis Use in Cancer Patients
The goal of this study is to determine the feasibility of a human observational study of orally administered cannabis use among cancer patients.
- Trial name
- NCT03617692
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- University of Colorado, Denver
Advanced Cancer, Advanced Solid Tumor
Oral Administration of STC-15 in Subjects With Advanced Malignancies
This Phase 1, multi-center, open-label, first-in-human study evaluates multiple ascending daily oral doses of STC-15 in Q3W treatment cycles in a 3+3 cohort design with dose levels determined by a modified Fibonacci algorithm.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Cancer
- Trial name
- NCT05584111
- Testing
- STC-15
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- STORM Therapeutics LTD
Cancer
Phase I Study of Disulfiram and Copper Gluconate for the Treatment of Refractory Solid Tumors Involving the Liver
OBJECTIVES: Primary Objectives Determine the safety and toxicity profile of co-administration of disulfiram and copper gluconate for the treatment of refractory malignancies that have metastasized to the liver.
- Trial name
- NCT00742911
- Testing
- Disulfiram, Copper Gluconate
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Utah
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.